Cover Image

Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endo...

Full description

Saved in:
Bibliographic Details
Main Authors: Herr, Ingrid (Author) , Salnikov, Alexey V. (Author) , Büchler, Markus W. (Author) , Moldenhauer, Gerhard (Author)
Format: Article (Journal)
Language:English
Published: 24 Aug 2012
In: OncoImmunology
Year: 2012, Volume: 1, Issue: 5, Pages: 741-743
ISSN:2162-402X
DOI:10.4161/onci.19532
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.4161/onci.19532
Verlag, kostenfrei, Volltext: https://doi.org/10.4161/onci.19532
Get full text
Author Notes:Ingrid Herr, Ariane Groth, Alexei V. Salnikov, Markus W. Büchler and Gerhard Moldenhauer
Description
Summary:TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
Item Description:Gesehen am 08.06.2018
Physical Description:Online Resource
ISSN:2162-402X
DOI:10.4161/onci.19532

Similar Items